The report provides a detailed analysis essential for establishing an Aminoglutethimide production plant. It encompasses all critical aspects necessary for Aminoglutethimide production, including the cost of Aminoglutethimide production, Aminoglutethimide plant cost, Aminoglutethimide production costs, and the overall Aminoglutethimide production plant cost. Additionally, the study covers specific expenditures associated with setting up and operating an Aminoglutethimide production plant. These encompass production processes, raw material requirements, utility requirements, infrastructure needs, machinery and technology requirements, manpower requirements, packaging requirements, transportation requirements, and more.
Aminoglutethimide is a medication that helps prevent the adrenal glands from producing specific hormones. It is mostly used to treat illnesses like Cushing’s syndrome, a disorder brought on by the body producing excessive amounts of the stress hormone cortisol. Furthermore, some patients with breast cancer may benefit from it, especially if the disease is not progressing (a condition known as carcinoma in situ). It is a member of the class of drugs called adrenal steroid synthesis inhibitors.
The key factor that influences the market growth of Aminoglutethimide is the ability of the substance to function as an adrenocortical steroid synthesis inhibitor for the treatment of Cushing’s syndrome, which significantly increases its demand in the pharmaceutical and medical industries. The widespread occurrence of Cushing’s syndrome and hormone-sensitive cancers, particularly breast cancer, is significantly increasing the demand for Aminoglutethimide.
It witnesses a significant demand from the aging population as they are more likely to be affected by hormonal imbalances and related diseases. Additionally, the drug’s ability to be effectively utilized in the treatment of breast and prostate cancer further amplifies its market presence. Overall, industrial Aminoglutethimide procurement is influenced by its application in the pharmaceutical and medical industries for the treatment of hormonal disorders, rising cases of hormonal disorders, the aging population, its efficacy in the treatment of breast and prostate cancer, and regulatory approvals.
Raw Material for Aminoglutethimide Production
According to the Aminoglutethimide production plant project report, the key raw material used in the production of Aminoglutethimide includes ethyl 2-chlorobutyrate.
Production Process of Aminoglutethimide
The extensive Aminoglutethimide production cost report consists of the following major industrial production process:
- Production from ethyl 2-chlorobutyrate: The production process of Aminoglutethimide starts with the reaction of ethyl 2-chlorobutyate with nitrobenzene in the presence of NaH and DMF to form ethyl 2-(4’-nitrophenyl)butyrate. The resulting compound undergoes alkylation with 3-bromopropionitrile in the presence of NaH and DMF to give the desired cyanoester. The cyanoester is reacted with polyphosphoric acid to give the cyclic imide. Finally, the nitro group of the imide is subjected to reduction by catalytic hydrogenation using palladium on carbon as the catalyst to produce Aminoglutethimide.
Aminoglutethimide, commercially known as Elipten, Cytadren, and Orimeten, is a white or creamy white crystalline powder having the molecular formula C13H16N2O2 and a molecular weight of 232.28 g/mol. It has a melting point in the range of 159-150 °C. It is almost insoluble in water, with an estimated water solubility of 0.371 mg/mL. It is easily soluble in most organic solvents, acetone, and 100% acetic acid, poorly soluble in ethyl acetate, 0.1N hydrochloric acid, and absolute alcohol. It has a log P value of around 1.3. The value of its dissociation constant, pKa, is 11.69. It releases toxic fumes of nitrogen oxide when heated to decomposition.
